SICLARI, OLIMPIA
SICLARI, OLIMPIA
Scienze Biomediche, Sperimentali e Cliniche 'Mario Serio'
Adjuvant chemotherapy: which patient? What regimen?
2013 Turner N; Biganzoli L; Malorni L; Migliaccio I; Moretti E; Pestrin M; Sanna G; Siclari O; Di Leo A.
Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer
2011 Camerini A; Donati S; Viacava P; Siclari O; Puccetti C; Tartarelli G; Valsuani C; De Luca F; Martini L; Cavazzana A; Amoroso D
Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma
2007 Sgambato A; Camerini A; Amoroso D; Genovese G; De Luca F; Cecchi M; Migaldi M; Rettino A; Valsuani C; Tartarelli G; Donati S; Siclari O; Rossi G; Cittadini A
Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients
2009 Camerini A; Rondini M; Garrone O; Valsuani C; Donati S; Siclari O; Sgambato A; Tartarelli G; Vincenti M; Mattiot VP; Porta RP; Puccetti C; Puccinelli P; Amoroso D.
p95HER2 truncated form in resected non-small cell lung cancer
2012 Cappuzzo F; Cho YG; Sacconi A; Alì G; Siclari O; Incarbone M; Destro A; Terracciano L; Fontanini G; Marchetti A; Roncalli M; Varella-Garcia M.
Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status
2010 Camerini A; Valsuani C; Mazzoni F; Siclari O; Puccetti C; Donati S; Rondini M; Tartarelli G; Puccinelli P; Di Costanzo F; Amoroso D.
Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report
2009 Valsuani C; Siclari O; Camerini A; Canale ML; Rondini M; Donati S; Puccinelli P; Tartarelli G; Puccetti C; Amoroso D
Targeting triple negative breast cancer: is p53 the answer?
2013 Turner, Natalie; Moretti, Erica; Siclari, Olimpia; Migliaccio, Ilenia; Santarpia, Libero; D'Incalci, Maurizio; Piccolo, Stefano; Veronesi, Andrea; Zambelli, Alberto; Del Sal, Gianni; Di Leo, Angelo
The continued evidence from overviews: What is the clinical utility?
2013 Turner N; Biganzoli L; Malorni L; Migliaccio I; Moretti E; Pestrin M; Sanna G; Siclari O; Di Leo A
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Adjuvant chemotherapy: which patient? What regimen? | 2013 | Turner N; Biganzoli L; Malorni L; Migliaccio I; Moretti E; Pestrin M; Sanna G; Siclari O; Di Leo A. | |
Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer | 2011 | Camerini A; Donati S; Viacava P; Siclari O; Puccetti C; Tartarelli G; Valsuani C; De Luca F; Martini L; Cavazzana A; Amoroso D | |
Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma | 2007 | Sgambato A; Camerini A; Amoroso D; Genovese G; De Luca F; Cecchi M; Migaldi M; Rettino A; Valsuani C; Tartarelli G; Donati S; Siclari O; Rossi G; Cittadini A | |
Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients | 2009 | Camerini A; Rondini M; Garrone O; Valsuani C; Donati S; Siclari O; Sgambato A; Tartarelli G; Vincenti M; Mattiot VP; Porta RP; Puccetti C; Puccinelli P; Amoroso D. | |
p95HER2 truncated form in resected non-small cell lung cancer | 2012 | Cappuzzo F; Cho YG; Sacconi A; Alì G; Siclari O; Incarbone M; Destro A; Terracciano L; Fontanini G; Marchetti A; Roncalli M; Varella-Garcia M. | |
Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status | 2010 | Camerini A; Valsuani C; Mazzoni F; Siclari O; Puccetti C; Donati S; Rondini M; Tartarelli G; Puccinelli P; Di Costanzo F; Amoroso D. | |
Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report | 2009 | Valsuani C; Siclari O; Camerini A; Canale ML; Rondini M; Donati S; Puccinelli P; Tartarelli G; Puccetti C; Amoroso D | |
Targeting triple negative breast cancer: is p53 the answer? | 2013 | Turner, Natalie; Moretti, Erica; Siclari, Olimpia; Migliaccio, Ilenia; Santarpia, Libero; D'Incalci, Maurizio; Piccolo, Stefano; Veronesi, Andrea; Zambelli, Alberto; Del Sal, Gianni; Di Leo, Angelo | |
The continued evidence from overviews: What is the clinical utility? | 2013 | Turner N; Biganzoli L; Malorni L; Migliaccio I; Moretti E; Pestrin M; Sanna G; Siclari O; Di Leo A |